13,14-dihydro-15-keto-tetranor Prostaglandin E2
- CAS No.
- 20675-85-8
- Chemical Name:
- 13,14-dihydro-15-keto-tetranor Prostaglandin E2
- Synonyms
- 13,14-dihydro-15-keto-tetranor Prostaglandin E2;13,14-dihydro-15-keto-tetranor Prostaglandin E2 Exclusive;Cyclopentanepropanoic acid, 3-hydroxy-5-oxo-2-(3-oxooctyl)-, [1R-(1α,2β,3α)]- (9CI)
- CBNumber:
- CB62589882
- Molecular Formula:
- C16H26O5
- Molecular Weight:
- 298.37
- MDL Number:
- MFCD18428006
- MOL File:
- 20675-85-8.mol
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS02,GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H225-H319 | |||||||||
| Precautionary statements | P210-P233-P240-P241-P242-P243-P264-P280-P303+P361+P353-P305+P351+P338-P337+P313-P370+P378-P403+P235-P501 | |||||||||
| NFPA 704 |
|
13,14-dihydro-15-keto-tetranor Prostaglandin E2 price More Price(3)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 13101 | 13,14-dihydro-15-keto-tetranor Prostaglandin E2 ≥95% | 20675-85-8 | 10μg | $98 | 2024-03-01 | Buy |
| Cayman Chemical | 13101 | 13,14-dihydro-15-keto-tetranor Prostaglandin E2 ≥95% | 20675-85-8 | 25μg | $232 | 2024-03-01 | Buy |
| Cayman Chemical | 13101 | 13,14-dihydro-15-keto-tetranor Prostaglandin E2 ≥95% | 20675-85-8 | 50μg | $437 | 2024-03-01 | Buy |
13,14-dihydro-15-keto-tetranor Prostaglandin E2 Chemical Properties,Uses,Production
Description
A common metabolic pathway for several prostaglandins (PG), including PGE2, involves the reduction of the double bond between C-13 and C-14 and oxidation of the hydroxyl group at C-15, producing 13,14-dihydro-15-keto PGs. The removal of four carbons at the α-terminus and oxidation of the terminal ω-carbon produces the abundant urinary metabolites, including tetranor PGEM.1 13,14-dihydro-15-keto-tetranor PGE2 is a potential metabolite of PGE2. It would be produced from the known metabolite 13,14-dihydro-15-keto PGE2 , which is known to have a short plasma half-life.2,3,4
References
1. Hamberg, M. Inhibition of prostaglandin synthesis in man Biochem. Biophys. Res. Commun. 49(3),720-726(1972).
2. Bothwell, W., Verburg, M., Wynalda, M., et al. A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: An indirect index of their in vivo disposition and pharmacokinetics J. Pharmacol. Exp. Ther. 220(2),229-235(1982).
3. Fitzpatrick, F.A., Aguirre, R., Pike, J.E., et al. The stability of 13,14-
4. Granstr?m, E., Hamberg, M., Hansson, G., et al. Chemical instability of 15-
13,14-dihydro-15-keto-tetranor Prostaglandin E2 Preparation Products And Raw materials
Raw materials
Preparation Products
13,14-dihydro-15-keto-tetranor Prostaglandin E2 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai Hongye Biotechnology Co. Ltd | 400-9205774 | sales@glpbio.cn | China | 6870 | 58 |
| Hangzhou Synstar pharmaceutical Technology CO.,Ltd | 0571-85361029 | synstar518@163.com | China | 1991 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 8740 | 58 |